Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -15.81
- Piotroski Score 3.00
- Grade Neutral
- Symbol (EYEN)
- Company Eyenovia, Inc.
- Price $0.11
- Changes Percentage (1.91%)
- Change -$0
- Day Low $0.10
- Day High $0.12
- Year High $2.57
Eyenovia, Inc., a clinical stage ophthalmic company, engages in developing therapeutics based on its proprietary microdose array print platform technology. The company focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. It focuses on the development of therapeutic indications for patients with progressive myopia and age-related near vision impairment or presbyopia indications; and microdose fixed combination ophthalmic pharmaceutical for mydriasis to address the eye exams with pupil dilation. The company's product candidates include MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); and MydCombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; and a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine and MicroLine in China and South Korea. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is headquartered in New York, New York.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/17/2025
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.74
- Trailing P/E Ratio -1.03
- Forward P/E Ratio -1.03
- P/E Growth -1.03
- Net Income $-27,261,096
Income Statement
Quarterly
Annual
Latest News of EYEN
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
European parliament reaches deal on approving von der Leyen's top team
European Parliament leaders have agreed to approve Ursula von der Leyen's top team, resolving threats from Socialists and the EPP. The deal paves the way for the new European Commission to take office...
By The Guardian | 1 day ago -
Eyenovia stock plummets following Phase III myopia trial failure
Eyenovia's stock price dropped significantly by more than two-thirds due to the failure of its Phase III study for myopia treatment. The CHAPERONE trial did not meet its primary endpoint, leading the ...
By Yahoo! Finance | 4 days ago -
Eyenovia Inc (EYEN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
CEO Michael Rowe discusses the expectations and key distinctions for the chaperone trial, focusing on efficacy, side effects, compliance, and systemic exposure. The trial aims to address myopia in chi...
By Yahoo! Finance | 1 week ago
